Dangers of GLP-1: How Receptor Agonists Affect Your Health

Overview of GLP-1 Receptor Agonist

GLP-1 receptor agonists, sometimes called GLP-1 analogs or incretin mimetics, are a class of medications designed to lower blood sugar and control appetite by stimulating the GLP-1 receptor in the body. These drugs imitate the natural hormone GLP-1, which is released by the intestines after eating and plays a key role in regulating glucose metabolism and promoting satiety. 

Now that we understand what GLP-1 receptor agonists are, let’s look at how they work inside the body to regulate blood sugar and appetite.

‍

How does a GLP-1 receptor agonist work?

GLP-1 receptor agonists mimic the action of the natural hormone GLP-1, enhancing the body's ability to regulate blood sugar and appetite. Their primary mechanisms include:

• Stimulating insulin secretion: They enhance insulin release from pancreatic beta cells in a glucose-dependent manner, lowering blood glucose levels.
  
  
• Suppressing glucagon secretion: They reduce glucagon release from pancreatic alpha cells, decreasing hepatic glucose production.
  
  
• Slow gastric emptying: It delays the rate at which the stomach empties its contents, leading to a more gradual absorption of glucose, which is beneficial for managing blood sugar levels in type 2 diabetes mellitus.
  
  
• Promoting satiety: They act on the brain's appetite centers, increasing feelings of fullness and reducing food intake.

Now that you know how these medications function, the next question is: who can benefit from GLP-1 therapy—and who should approach it with caution?

‍

Who should consider using a GLP-1 agonist?

GLP-1 receptor agonists are mainly prescribed for individuals who need better control over their blood sugar or weight, especially those dealing with type 2 diabetes mellitus. However, their use must be carefully evaluated based on medical need and overall health.

They are considered for:

• Patients with type 2 diabetes: Individuals whose blood sugar remains high despite using first-line diabetic medications like metformin may benefit from adding a GLP-1 agonist.
  
  
• Individuals with obesity: Adults with a body mass index (BMI) of 30 or higher, or those with a BMI over 27, may opt for GLP-1 for weight loss.

Even for the right candidates, it’s essential to understand the possible risks. Let’s explore the side effects associated with GLP-1 receptor agonists.

‍

Side Effects of GLP-1 on Diabetes

GLP-1 receptor agonists are effective medications for managing type 2 diabetes and supporting weight loss. However, they can cause side effects, ranging from mild to serious, like:

Gastrointestinal issues

Nausea, vomiting, diarrhea, and constipation are frequently reported. These symptoms often occur at the start of treatment and may lessen over time. ​

Appetite changes

Some individuals experience reduced appetite, which can contribute to weight loss.​

Headaches and dizziness

These symptoms may occur, particularly during the initial stages of therapy.​

Injection site reactions

Redness, swelling, or discomfort at the injection site can happen, but is usually mild.​

Pancreatitis

There have been reports linking GLP-1 receptor agonists to pancreatitis, an inflammation of the pancreas.

Kidney issues

Severe dehydration from gastrointestinal adverse events may lead to kidney problems.

Gallbladder problems

Some users have experienced gallstones or inflammation of the gallbladder. 

Among the various side effects, gastrointestinal issues are particularly common and often the most troublesome. Here’s what you need to know.

‍

Risk of gastrointestinal issues with GLP-1 agonists

As discussed earlier, GLP-1 receptor agonists slow digestion, allowing food to remain longer in the stomach.  They do this by reducing the strength of stomach muscle contractions. As a result, food stays longer in the stomach before moving into the intestines.

While this helps control blood sugar, it can also lead to gastrointestinal discomfort in some patients.

The main gastrointestinal issues include:

• Nausea
  When food sits in the stomach for too long, it can stretch the stomach wall and trigger feelings of nausea.
  
  
• Vomiting
  In some patients, delayed emptying causes enough stomach discomfort to lead to vomiting, especially if meals are large or eaten quickly.
  
  
• Diarrhea
  Slower digestion can disrupt the normal rhythm of the intestines, leading to episodes of diarrhea as the body tries to adjust.
  
  
• Constipation
  In other cases, digestion becomes sluggish overall, making bowel movements less frequent and harder to pass.

While managing side effects is important, it’s equally critical to understand how GLP-1 medications stack up against other diabetes treatments. Let’s compare them. 

‍

Difference Between GLP-1 Receptor Agonists and Other Diabetes Medicines

How They Work

• GLP-1 Receptor Agonists mimic a natural hormone (glucagon-like peptide-1) to increase insulin only when needed, suppress glucagon (which raises blood sugar), and slow digestion to help with weight control.
• Other Diabetes Medicines either add insulin directly or stimulate the pancreas to release insulin constantly, which may lead to less precise control.

Effect on Appetite

• GLP-1 Receptor Agonists reduce hunger and help you feel full sooner, making them useful for both blood sugar and weight management.
• Other Diabetes Medicines typically don’t affect hunger or satiety.

Risk of Low Blood Sugar

• GLP-1 Receptor Agonists have a lower risk of hypoglycemia because they adjust insulin output based on blood sugar levels.
• Other Diabetes Medicines, such as insulin or sulfonylureas, carry a higher risk of low blood sugar.

Effect on Weight

• GLP-1 Receptor Agonists often lead to weight loss, making them a dual-purpose treatment for diabetes and obesity.
• Other Diabetes Medicines can lead to weight gain, especially when insulin is involved.

Heart Health Benefits

• GLP-1 Receptor Agonists (certain types) have shown protective effects for cardiovascular health.
• Other Diabetes Medicines generally do not offer specific heart-related benefits.

Primary Focus of Treatment

• GLP-1 Receptor Agonists address blood sugar control, appetite regulation, and weight management.
• Other Diabetes Medicines are mostly focused on lowering blood glucose levels only.

Among the many diabetes treatments, insulin remains the most common, but it works very differently from GLP-1 therapies. Let’s take a closer look at how GLP-1 receptor agonists compare to insulin.

‍

What makes GLP-1 medications different from insulin?

GLP-1 receptor agonists and insulin both help manage blood sugar, but they work in very different ways, particularly in people with type 2 diabetes mellitus and obesity. 

Unlike insulin therapy, GLP-1 agonists stimulate insulin release only when blood sugar levels are elevated, reducing the risk of hypoglycemia.

Because of this, GLP-1 agonists carry a lower risk of causing dangerously low blood sugar compared to insulin injections, making them safer for weight-loss drugs. 

Another key difference is their effect on weight. GLP-1 medications often help patients lose weight by reducing hunger and promoting fullness, while insulin therapy can lead to weight gain by encouraging fat storage.

Some GLP-1 receptor agonists have also shown benefits for heart health, lowering the risk of major cardiovascular events, which is an important consideration for individuals with type 2 diabetes mellitus. Insulin, while essential for blood sugar control, does not offer these additional protective effects.

While insulin focuses solely on blood sugar control, GLP-1 receptor agonists may also offer important protection for heart health. Let’s explore this next.

‍

What are the cardiovascular effects of GLP-1 receptor agonists?

Beyond their effects on blood sugar and weight management, GLP-1 receptor agonists may also lower cardiovascular risk, an advantage that sets them apart from many older diabetes treatments.

In fact, the SELECT trial published in the New England Journal of Medicine found that weekly semaglutide reduced the risk of major cardiovascular death by 20% compared to placebo in adults with overweight or obesity and existing heart disease.

This significant benefit highlights why GLP-1 receptor agonists are increasingly considered for patients with metabolic and cardiovascular risks. However, factors like cost, side effects, and the need for injections must still be carefully weighed.

While the cardiovascular benefits of GLP-1 therapies are promising, they are not without important considerations. Before starting treatment, it’s essential to understand what to expect and how to prepare for safe and effective use.

‍

What should you know before taking GLP-1 medications?

Before starting GLP-1 therapy, especially with glucagon-like peptide 1 receptor agonists, it’s important to be aware of a few specific facts: 

• You may experience nausea at the beginning
  Nausea is common when starting treatment, but it often improves after a few weeks as your body adjusts.
  
  
• You will likely need to start with a low dose
  Most GLP-1 medications, including semaglutide and liraglutide, begin at a lower dose that is gradually increased to reduce gastrointestinal adverse effects.
  
  
• You must monitor for signs of dehydration
  Vomiting or diarrhea can sometimes cause dehydration, so drinking enough fluids is essential.
  
  
• The medication usually requires injections
  While some GLP-1 therapies are oral, most are delivered by injection once daily or weekly, and they are commonly used to treat type 2 diabetes mellitus.
  
  
• GLP-1 is not suitable for everyone
  It is not recommended for those with certain contraindications associated with glucagon-like peptide-1 receptor agonists or certain genetic conditions like MEN 2.
  
  
• Lifestyle changes still matter
  Diet and exercise continue to play a major role in the effectiveness of GLP-1 therapy. 

Taking these points into account, let’s look at specific precautions you and your doctor should discuss before beginning GLP-1 therapy.

‍

What precautions should be taken before starting GLP-1 therapy?

Before starting GLP-1 therapy, certain precautions must be taken to ensure safety and effectiveness, particularly for people with type 2 diabetes. Start by:

• Screening for thyroid and pancreatic conditions
  A history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN 2), or pancreatitis should be ruled out, as GLP-1 therapy may not be safe in these cases.
  
  
• Reviewing current medications
  Some drugs, such as insulin or sulfonylureas, may need dose adjustments to avoid the risk of low blood sugar when combined with GLP-1 agonists.
  
  
• Starting at the lowest dose of glucagon-like peptide-1 receptor agonist
  Beginning with a low dose helps minimize side effects like nausea and vomiting. The dose of glucagon-like peptide 1 receptor agonists can be gradually increased based on tolerance.
  
  
• Planning for lifestyle changes
  A balanced diet, regular exercise, and hydration are important to support the benefits of GLP-1 medications and reduce gastrointestinal side effects.
  
  
• Understanding administration requirements
  Most GLP-1 drugs are given by injection. Patients should be prepared for self-injection of glucagon-like peptide-1 receptor agonists.

While many can benefit from GLP-1 therapy, certain individuals should avoid it altogether. 

‍

Who should avoid using a GLP-1 receptor agonist?

Not everyone is a good candidate for GLP-1 therapy. 

If you have a history of medullary thyroid carcinoma or a genetic condition like multiple endocrine neoplasia syndrome type 2 (MEN 2), your risk of developing thyroid tumours may be higher. In such cases, your doctor may recommend avoiding GLP-1 therapy.

Note: If you have a personal or family history of thyroid disorders, it’s important to mention it during your consultation, even if you’re unsure whether it’s directly related.

Beyond thyroid concerns, other factors can also influence your suitability for treatment. A previous episode of pancreatitis, for example, can raise the risk of pancreatic complications with GLP-1 use. 

Especially for people with type 1 diabetes, where insulin replacement is essential, these medications are not at all recommended. 

Also, if you are pregnant, planning a pregnancy, or living with severe gastrointestinal issues, consult your doctor, as they may advise you to avoid GLP-1 therapies altogether.

‍

Before You Go...

GLP-1 receptor agonists offer promising benefits, but they come with real risks that can’t be overlooked. If you found Understanding the GLP-1 Receptor Agonist: Effects, Risks, and Diabetes Medicine helpful, we encourage you to continue exploring our research-based articles to make informed decisions about your health.

‍

About Institute of Medical Physics

The Institute of Medical Physics, founded by Dr. Emanuel Paleco, is a premier medical laboratory specialising in Medical and Aesthetic Laser Science. With a flagship clinic in King’s Cross and additional locations in North London and Essex, the Institute is at the forefront of laser science innovation.

Experience advanced laser science and innovative medical treatments. Book a consultation with Dr. Emanuel Paleco and his expert team at the Institute of Medical Physics. Contact us today to schedule your appointment and start your journey towards rejuvenation.